Customise results display
Results 1-5 of 5 (Search time: 0.003 seconds).
|20-Jul-1998||In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors||Martiniello-Wilks, R; Garcia-Aragon, J; Daja, MM; Russell, P; Both, GW; Molloy, PL; Lockett, LJ; Russell, PJ|
|1-Jan-2002||Transcription-targeted gene therapy for androgen-independent prostate cancer||Martiniello-Wilks, R; Tsatralis, T; Russell, P; Brookes, DE; Zandvliet, D; Lockett, LJ; Both, GW; Molloy, PL; Russell, PJ|
|1-Mar-2013||Gastrointestinal pathogen distribution in symptomatic children in Sydney, Australia||Fletcher, S; Van Hal, S; Andresen, D; McLaws, ML; Stark, D; Harkness, J; Ellis, J|
|1-Jan-2004||Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease||Martiniello-Wilks, R; Dane, A; Voeks, DJ; Jeyakumar, G; Mortensen, E; Shaw, JM; Wang, XY; Both, GW; Russell, PJ|
|1-Dec-2004||Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer||Martiniello-Wilks, R; Wang, XY; Voeks, DJ; Dane, A; Shaw, JM; Mortensen, E; Both, GW; Russell, PJ|